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Eccrine squamous syringometaplasia (ESS) is defined 
as metaplasia of the eccrine ductal epithelium into squa-
mous epithelial cells. It has been reported in patients 
with malignancy receiving chemotherapeutic agents. 
Histologically, the lesions exhibit transformation of 
normal cuboidal epithelial cells into 2 or more layers of 
squamous epithelial cells (1). Tegafur/Gimeracil/Otera-
cil (Teysuno, TS-1; Jeil Pharmaceutical Co. Ltd, Seoul, 
South Korea) is a combined oral chemotherapeutic agent 
indicated for advanced gastric cancer, and its use has 
been expanded to colorectal, lung, laryngeal, pancreatic, 
and biliary cancers. 
CASE REPORT
A 68-year-old woman presented with several match head-sized 
papules with surrounding erythema and central confluence along 
the periorbital area (Fig. 1). The skin lesion was mildly pruritic 
and lasted for 10 days. She had a history of advanced gastric 
cancer (stage II2a) and had previously undergone subtotal gast-
rectomy. The patient was started on adjuvant chemotherapy with 
TS-1 with 3 capsules at a time, twice daily, for 28 days (Tegafur 
20 mg/Gimerasil 5.8 mg/Oteracil 19.6 mg),and 2 weeks thereaf-
ter, the skin eruption had appeared. She had no other remarkable 
medical history. Skin biopsy revealed metaplastic eccrine ducts 
in the dermis with intercellular bridge formation (Fig. 2A). On 
high power view, eccrine ductal epithelia showed mitotic figures 
and necrotic duct cells. Other parts of the specimen demonstra-
ted transformation of cuboidal epithelium into 2 or more layers 
of squamous cells with intraductal keratinisation (Fig. 2B–D). 
Considering the patient’s history of internal malignancy and 
histological features, the final diagnosis was ESS. 
DISCUSSION
Chemotherapy-associated eccrine reactions usually 
arise 2 to 30 days after the agent’s administration. 
They may present as non-specific features, ranging 
from erythematous papules on the periorbital area to 
diffuse patches on the intertriginous areas (2). The 
lesions usually spontaneously resolve within 15 days 
with mild desquamation and postinflammatory hyper-
pigmentation. There have been reports of successful 
treatment with topical and systemic steroids. ESS has 
been reported with chemotherapeutic agents including 
bleomycin, cytarabine, cisplatin, and tyrosine kinase 
inhibitors (3). Recently, there have been reports of 
ESS in patients with metastatic melanoma receiving 
vemurafenib and dabrafenib (4). However, it does not 
seem to have a strong association with any particular 
chemotherapeutic agent or malignancy, and some 
cases are associated with infection or inflammatory 
conditions. 
For the diagnosis of ESS, histological examinations 
are important to exclude squamous cell carcinoma 
(SCC). Three distinguishable features suggestive of 
ESS include epidermal dystrophy, neutrophilic ec-
crine hidradenitis, and necrosis of eccrine ducts. Our 
patient had both early and well-established patterns of 
ESS, showing hyperplastic eccrine ducts with mitotic 
figures and intraductal keratinisation within the areas 
of squamous metaplasia. 
The main component of TS-1, tegafur, is the prodrug 
of the active substance fluoruracil (5-FU), and other 
components are for reducing gastrointestinal toxicity. 
In addition to its use in gastric cancer, TS-1 recently 
showed successful outcomes in head and neck SCC. 
Therefore, it would seem paradoxical for such a drug 
to cause squamous transformation in the eccrine duct 
lumen. However, in vitro data have demonstrated that 
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Fig. 1. Several match head-sized erythematous papules and nodules along 
the periorbital area. A written permission is given to publish this figure.
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TS-1 inhibits expression of Akt/ NFkB pathways, which 
may lead to the activation of the MAPK pathway, 
leading to squamous cell proliferation (5, 6).
Currently, the underlying pathomechanism of ESS 
is yet to be elucidated. Direct toxic effects of the 
chemo therapeutic drug on the eccrine gland may be 
responsible for the secondary changes. Considering 
the paucicellular inflammatory cell inflammation sur-
rounding the eccrine duct, ductal necrosis due to high 
concentrations of the drug within glandular structures 
may induce squamous metaplasia. Indeed, there have 
been reports of systemically administrated 5-FU cau-
sing squamous metaplasia of the lacrimal gland which 
eventually cause canaliculus obstruction (7). 
To our knowledge, this is the first case of ESS repor-
ted as a result of treatment with TS-1. 
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Fig. 2. Histopathologic features of 
the patient. A) A biopsy specimen 
shows metaplastic eccrine ducts in 
the dermis with intercellular bridges. 
B) Hyperplastic eccrine ducts with 
mitotic figures and necrotic duct cells. 
C) Transformation of eccrine cuboidal 
epithelium into 2 or more layers of 
squamous cells. D) Metaplastic eccrine 
duct with intraductal keratinisation 
(Haematoxylin-eosin stain, A, × 100, 
B, C, D, × 400).
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